Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Size

• The Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market is expected to reach USD 2.23 Billion by 2033 from USD 1.30 Billion in 2025, growing with a substantial CAGR of 7.97% in the forecast period of 2026 to 2033
• The Middle East and Africa Blood Plasma & Plasma-Derived Medicinal Products market growth is strongly driven by the rising prevalence of chronic, autoimmune, and rare diseases, such as immunodeficiency disorders, hemophilia, and neurological conditions. Increasing diagnosis rates, an aging population, and improved access to advanced therapies are significantly boosting demand for plasma-derived treatments including immunoglobulins, albumin, and clotting factors.
• Market expansion is further supported by advancements in plasma collection infrastructure and fractionation technologies, along with favorable regulatory frameworks and strong healthcare expenditure in the region. The growing number of plasma donation centers, coupled with increasing investments by major biopharmaceutical companies, is enhancing plasma supply availability and supporting the large-scale production of high-value plasma-derived medicinal products.

Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Analysis

• Increasing investments in advanced healthcare infrastructure and biopharmaceutical manufacturing are a key trend driving demand for blood plasma and plasma-derived medicinal products in Middle East and Africa. Modern healthcare systems increasingly rely on high-quality plasma-based therapies to support the treatment of immunological, neurological, hematological, and rare diseases.
• Blood plasma and plasma-derived medicinal products play a critical role in life-saving and chronic disease therapies, supporting applications such as immunoglobulin replacement therapy, hemophilia treatment, and critical care. Their indispensable role in modern medicine makes them essential to healthcare system resilience and therapeutic innovation across the region.
• The Saudi Arabia is the dominant country in the North America Blood Plasma & Plasma-Derived Medicinal Products market, accounting for 22.87% market share in 2027, driven by its strong plasma collection network, presence of leading biopharmaceutical companies, high healthcare expenditure, and favorable regulatory environment.
• The Saudi Arabia is also the fastest-growing country in the region, registering a CAGR of 8.41%, reflecting rising demand for plasma-derived therapies, increasing prevalence of chronic and rare diseases, and continued investments in plasma collection and processing infrastructure.
• In 2025, the Immunoglobulins segment is dominate the Middle East and Africa blood plasma and plasma-derived medicinal products market with a market share of 41,35%, driven by its extensive use in treating immune deficiencies, autoimmune disorders, and neurological diseases. Increasing diagnosis rates and growing demand for IVIG therapies continue to support its leading position in the market.

Report Scope and Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Segmentation     

Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Trends

“Integration of Modern Healthcare Infrastructure”

• Expansion of advanced hospital networks and specialty care centers is driving higher adoption of plasma-derived medicinal products, as modern facilities are better equipped to administer complex biologic therapies such as immunoglobulins, clotting factors, and albumin.
• Improved cold-chain logistics and storage infrastructure across healthcare systems is supporting the safe handling, transportation, and long-term preservation of plasma-derived products, ensuring product efficacy and reducing wastage.
• Integration of digital health systems and electronic medical records (EMRs) is enhancing treatment tracking, dosing accuracy, and patient monitoring, enabling more efficient and outcome-based use of plasma-derived therapies.
• Strengthening of reimbursement frameworks and insurance coverage within modern healthcare ecosystems is improving patient access to high-cost plasma-derived treatments, particularly for chronic, rare, and life-threatening conditions.
• Adoption of standardized treatment protocols and regulatory-compliant practices in upgraded healthcare infrastructures is ensuring consistent quality, safety, and clinical effectiveness of plasma-derived medicinal products across hospitals and infusion centers.

Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Dynamics

Driver

“Rising Prevalence Of Rare And Chronic Diseases”

• The increasing prevalence of rare and chronic diseases globally is a critical driver for the growth of the blood plasma and Plasma-Derived Medicinal Products (PDMPs) market. Diseases such as Primary Immunodeficiency (PID), hemophilia, von Willebrand disease, alpha-1 antitrypsin deficiency, and various autoimmune and neurological disorders are being diagnosed more frequently due to advancements in diagnostic technologies and improved awareness among healthcare providers and patients.
• Demographic shifts, particularly the aging global population, further amplify demand for PDMPs. Older adults are more prone to chronic and degenerative conditions such as liver cirrhosis, multiple myeloma, chronic inflammatory disorders, and neurological diseases, many of which rely on plasma-derived products for effective management.
• These conditions often require long-term, sometimes lifelong, treatment with plasma-derived therapies such as immunoglobulins, coagulation factors, and albumin. For instance, patients with PID rely heavily on Intravenous Immunoglobulin (IVIG) to maintain immune function, while those with hemophilia require regular infusions of clotting factors to prevent bleeding episodes. The global aging population further contributes to this trend, as older adults are more susceptible to chronic conditions such as liver cirrhosis, multiple myeloma, and chronic inflammatory diseases that also require plasmaderived products. In addition, governments and health organizations are increasingly recognizing the burden of rare diseases, resulting in improved disease surveillance, the establishment of national registries, and more inclusive reimbursement policies.

For Instances

• In April 2025, CDC data showed that 76.4% of U.S. adults had at least one chronic condition, with 51.4% facing multiple conditions. This rising trend, including among young adults, highlights the growing burden of chronic diseases such as hemophilia, primary immunodeficiency diseases, and von willebrand disease, demanding greater focus on lifelong care and management.
• In March 2025, research featured in PMC emphasized the substantial global impact of rare diseases, collectively affecting millions worldwide, especially pediatric patients. The review highlights the complex interplay between genetic and environmental factors, as well as the persistent diagnostic challenges and delays. Despite advancements in genomic medicine and orphan drug development, effective treatments remain limited, necessitating comprehensive, multidisciplinary care approaches. This reinforces the ongoing struggle for timely and accurate diagnoses for these often-debilitating conditions
• In February 2025, a study focused on the Middle East and North Africa (MENA) region, published in PMC, underscores the disproportionately high prevalence of rare diseases in this area due to genetic and cultural factors, such as consanguinity. The report highlights critical challenges faced by patients, including limited disease knowledge and delayed diagnoses, despite governments and organizations implementing incentives for orphan drug development. This highlights that, despite global efforts, access to timely treatment for rare diseases remains limited in many region.

Restraint/Challenge

“High Cost and Complex Manufacturing Process”

• The high cost and complexity associated with the manufacturing of Plasma-Derived Medicinal Products (PDMPs) represent a major restraint in the global market. The production process involves multiple intricate stages, beginning with the collection of human plasma under strict medical and regulatory conditions. Each donation must be thoroughly tested for pathogens and other contaminants to ensure the safety and integrity of the source material. The subsequent fractionation and purification processes are technologically advanced, requiring specialized equipment, skilled labor, and a sterile environment.
• Manufacturing can take up to 12 months, from plasma collection to the final product, with each step needing rigorous quality control and compliance with international Good Manufacturing Practices (GMP). In addition, the need for cold-chain logistics throughout storage, transportation, and distribution further increases operational costs. These factors collectively lead to high capital investment and operational expenses, limiting the ability of smaller manufacturers and emerging economies to enter or expand in the market.

For Instances,

• A detailed analysis by Aykon Biosciences highlights that pharmaceutical manufacturing, particularly for complex biologics such as plasma-derived products, faces significant cost management challenges due to rising raw material and labor expenses, combined with increasingly stringent regulatory compliance requirements. The demand for personalized medicine and specialized therapies further drives the need for new, often expensive manufacturing processes. This necessitates substantial investment in advanced technology, highly trained personnel, and rigorous quality control measures, adding considerably to the final product cost.

Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Scope

The Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market is segmented into six notable segments based on product, application, processing technology, mode, end user, and distribution channel.

• By Product

On the basis of product, immunoglobulins, coagulation factors, albumin, protease inhibitors, monoclonal antibodies, and other plasma derived proteins.

In 2026, the Immunoglobulins segment is expected to dominate the market with a 41.24% market share and Coagulation Factors segment is growing with highest CAGR of 8.5% due to the rising prevalence of primary and secondary immunodeficiency disorders, increasing use in neurological and autoimmune diseases such as Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP), and expanding off-label applications.

• By Application

On the basis of application, the market is segmented into immunology, hematology, critical care, neurology, pulmonology, haemato-oncology, rheumatology, and other applications.

In 2026, the Immunology segment is expected to dominate the market with a 31.34% market share and Neurology segment is growing with highest CAGR OF 9.0% due to the widespread use of immunoglobulin therapies in treating primary and secondary immunodeficiencies, growing demand for antibody replacement therapies, and increasing global awareness and diagnosis of immune-related conditions.

• By Processing Technology

On the basis of processing technology, the market is segmented into ion exchange chromatography, affinity chromatography, cryoprecipitation, ultrafiltration, and microfiltration.

In 2026, the ion exchange chromatography segment is expected to dominate the global Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market with a 32.31% market share and Ultrafiltration is growing with highest CAGR of 8.5% due to its high selectivity, scalability, and efficiency in purifying plasma proteins, particularly immunoglobulins and coagulation factors.

• By Mode

On the basis of mode, the market is segmented into modern and traditional plasma fractionation.

In 2026, the Modern segment is expected to dominate the global Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market with a 72.11% market share and CAGR 8.1% due to the adoption of advanced purification techniques like chromatography and filtration, which ensure higher product purity, safety, and viral inactivation efficiency.

• By End user

On the basis of end user, the market is segmented into hospitals & clinics, research labs, academic institutes, and others.

In 2026, the Hospitals & Clinics segment is expected to dominate the Global Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market with a 66.04% market share and Research Labs is growing with highest CAGR 8.6% due to the high volume of patient admissions for immunological, hematological, and critical care treatments, immediate access to plasma therapies, and the presence of specialized infrastructure for administering complex biologics like IVIG and clotting factor.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others.

In 2026, the Direct Tenders segment is expected to dominate the global Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market with a 53.44% market share and CAGR 8.2% due to increased government procurement initiatives, bulk purchasing by public healthcare institutions, and national immunization or plasma therapy programs that rely on centralized distribution for cost efficiency, supply security, and streamlined regulatory compliance.

Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Regional Analysis

• The Saudi Arabia dominates the Middle East and Africa market with a significant share of 22.95% in 2026, driven by high healthcare spending, advanced plasma collection & fractionation infrastructure, and broad access to specialty treatments. Strong reimbursement mechanisms and a large patient base for immunological and rare disease therapies further reinforce its leadership.
• U.A.E is strengthening its position through expanded plasma donation programs, increased capacity for plasma fractionation, and policies supporting equitable access to biologic therapies. Improvements in healthcare infrastructure and rising demand for plasma-derived products for chronic and autoimmune conditions are contributing to steady market growth.
• Across Middle East and Africa, enhanced regulatory frameworks, clinical research initiatives, and strategic collaborations among biopharma companies are accelerating product approvals and market entry. Continued investment in advanced technologies and quality control systems is enabling the broader adoption of plasma-derived medicinal products region-wide.

Saudi Arabia Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Insight

The Saudi Arabia blood plasma and plasma-derived medicinal products market is driven by a strong plasma collection network, advanced biopharmaceutical manufacturing capabilities, and high healthcare expenditure. Rising prevalence of chronic, autoimmune, and rare diseases is fueling sustained demand for immunoglobulins, clotting factors, and albumin therapies. Supportive reimbursement policies, continuous technological advancements in plasma fractionation, and the presence of major industry players further strengthen market growth and ensure steady expansion across therapeutic applications.

U.A.E Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Insight

The U.A.E. blood plasma and plasma-derived medicinal products market is supported by expanding healthcare infrastructure and growing demand for therapies used in immunodeficiency, neurological, and rare disease treatment. Government initiatives to strengthen plasma collection programs and reduce reliance on imports are improving domestic supply capabilities. Rising awareness of plasma-based therapies, favorable reimbursement frameworks, and ongoing investments in biologics manufacturing are contributing to steady market growth and improved patient access nationwide.

South Africa Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Insight

The South Africa blood plasma and plasma-derived medicinal products market is supported by expanding healthcare infrastructure and growing demand for therapies used in immunodeficiency, neurological, and rare disease treatment. Government initiatives to strengthen plasma collection programs and reduce reliance on imports are improving domestic supply capabilities. Rising awareness of plasma-based therapies, favorable reimbursement frameworks, and ongoing investments in biologics manufacturing are contributing to steady market growth and improved patient access nationwide.

Egypt Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Insight

The Egypt blood plasma and plasma-derived medicinal products market is supported by expanding healthcare infrastructure and growing demand for therapies used in immunodeficiency, neurological, and rare disease treatment. Government initiatives to strengthen plasma collection programs and reduce reliance on imports are improving domestic supply capabilities. Rising awareness of plasma-based therapies, favorable reimbursement frameworks, and ongoing investments in biologics manufacturing are contributing to steady market growth and improved patient access nationwide.

Israel Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Insight

The Israel blood plasma and plasma-derived medicinal products market is supported by expanding healthcare infrastructure and growing demand for therapies used in immunodeficiency, neurological, and rare disease treatment. Government initiatives to strengthen plasma collection programs and reduce reliance on imports are improving domestic supply capabilities. Rising awareness of plasma-based therapies, favorable reimbursement frameworks, and ongoing investments in biologics manufacturing are contributing to steady market growth and improved patient access nationwide.

Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market Share

The blood plasma & plasma derived medicinal products industry is primarily led by well-established companies, including:

• CSL Limited (Australia)
• Takeda Pharmaceutical Company Limited (Japan)
• Grifols, S.A. (Spain)
• Octapharma AG (Switzerland)
• Kedrion S.p.A. (Italy)
• ADMA Biologics, Inc. – (U.S.)
• Aegros (Australia)
• Bharat Serums (India)
• Biotest AG (Germany)
• Fresenius Kabi AG (Germany)
• GC Biopharma Corporate (South Korea)
• ICHOR (India)
• Intas Pharmaceuticals Ltd (India)
• Kamada Pharmaceuticals (Israel)
• KM Biologics (Japan)
• LFB (France)
• PlasmaGen BioSciences Pvt. Ltd. (India)
• Proliant Health & Biologicals (U.S.)
• Promea (India)
• Reliance Life Sciences (India)
• Sichuan Yuanda Shyuang Pharmaceutical Co., Ltd. (China)
• SK Plasma (South Korea)
• Synthaverse S.A. (Poland)
• Taibang Bio Group Co., Ltd. (China)
• VIRCHOW BIOTECH (India)

Latest Developments in Middle East and Africa Blood Plasma and Plasma Derived Medicinal Products Market

• In November 2025, CSL announced a planned ~USD 1.5 billion capital investment in the U.S. to expand its manufacturing footprint for plasma-derived therapies over the next five years. This investment is intended to strengthen domestic production, secure supply chains for critical products like immunoglobulins and other plasma-derived medicines, and generate hundreds of skilled jobs in the U.S. manufacturing sector. This builds on more than USD 3 billion already invested in U.S. operations since 2018.
• In October 2025, CSL’s Broadmeadows plasma fractionation facility in Victoria, Australia was recognized as a Facility of the Year winner by the International Society for Pharmaceutical Engineering (ISPE) in 2025. This facility one of the world’s largest for plasma processing uses advanced automation, robotics, digital twin technology, and sustainability features to significantly boost plasma processing capacity (over 10 million liters annually) and improve manufacturing efficiency.
• In February, Octapharma completed a USD 216 million USDexpansion at its Vienna site, increasing production capacity by 50%, adding 160 jobs, and enhancing packaging, visual inspection, and logistics facilities—strengthening global supply of plasmaderived therapies for haemophilia, immunology, and critical care.
• In November 2024, CSL Plasma expanded its adoption of the advanced Rika Plasma Donation System across six U.S. donation centers near Denver, Colorado. These new devices, developed jointly with Terumo Blood & Cell Technologies, cut collection times by ~30% while improving donor comfort, safety, and efficiency.
• In June 2024, Takeda announced a USD 30 million expansion of its Los Angeles plasma‑fractionation facility, its global leader per capacity. This upgrade is expected to add up to 2 million liters/year of production volume, helping to meet rising global demand for plasma‑derived therapies used in treating immunodeficiencies and bleeding disorders.

SKU-74265